Table 2.
Increased pituitary E2F1 and PTTG1 expression in paired Rb+/− and WT mice
| Genotype | Age (months)
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2
|
3
|
6
|
7
|
10
|
||||||||||||
| Rb+/− | WT | Rb+/− | WT | Rb+/− | WT | Rb+/− | WT | Rb+/− | WT | Rb+/− | WT | Rb+/− | WT | Rb+/− | WT | |
| Gender | M | M | F | F | M | M | F | F | F | F | F | F | M | M | M | M |
| Pituitary tumor | No | No | No | No | Yes | Yes | No | Yes | ||||||||
| Pituitary E2F1 expression (%)a | 12 | 6 | 10 | 5 | 8 | 4 | 6 | 1 | 16 | 10 | 15 | 8 | 23 | 14 | 10 | 7 |
| Pituitary PTTG1 expression (%)a | 9 | 3 | 6 | 0.1 | 2 | 0.7 | 3 | 1 | 18 | 0.2 | 6 | 3 | 14 | 7 | 6 | 0.1 |
E2F1 and PTTG1 overexpression were observed in eight of 11 Rb+/− mice as assessed by confocal immunofluorescence. In three Rb+/− and WT mice, E2F1 was unchanged and PTTG1 was undetectable (data not shown). E2F1 expression was 12.8 ± 1.4 in Rb+/− vs. 8.8 ± 1.5 in WT (n = 11; P < 0.01); PTTG1 expression was 5.8 ± 1.8 in Rb+/− vs. 1.4 ± 0.7 in WT (n = 11; P < 0.05). F, Female; M, male.
a
Percentage of immunopositive pituitary cells.